As a condition with fewer treatment options, myelodysplastic syndrome (MDS) patients require long-term and treatment resistant solutions. Aiming to address this unmet need, Faron Pharmaceuticals continues to work on promising lead asset bexmarilimab.
Bexmarilimab is a humanized antibody that binds to receptors, myeloid cells and macrophages. It functions by priming the tumor microenvironment for optimal antitumor immune responses, in both hematological malignancies and solid tumors.

Speaking to the In Vivo podcast, Jalkanen stated that after a highly positive set of Phase II data, the company has already contacted the US Food and Drug Administration (FDA) asking, “Hey, what’s next?”
Focusing not only on the professional growth of the company, Jalkanen also highlights personal growth in his career progression, leading to his current role as CEO, which he began in May 2024 when his father and Faron founder Markku Jalkanen retired.
Jalkanen explained how his practical medical background provides him with a uniquely optimal position for investors, as he can explain trials in layman’s terms, which subsequently ensures Faron receives the funding needed to progress clinical trials.
He talked about his transition to CEO when the company faced extreme financial difficulties, stating that the company is now in a strong financial position.
Time-stamps:
00:55 Introduction
01:44 The urgency Of Bexmab
03:10 Clinical data and Phase II results
06:51 Learning from failure
12:18 Looking ahead